Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
매출 4.6억. 세부 수치와 가이던스는 원문에서 확인하세요.
EPS 컨센서스 0.08 · 매출 컨센서스 4.1억. 발표 후 실제치와 비교하세요.
매출 4.4억. 세부 수치와 가이던스는 원문에서 확인하세요.
신규 편입 · 포트폴리오 비중 0.01%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
매출 4억. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $16.3 · 10 analysts
Stored first · Google News · Yahoo Finance (English)
LifeStance Health Flirts With Latest Buy Point Despite Ongoing Stock Market Weakness
LifeStance Health Flirts With Latest Buy Point Despite Ongoing Stock Market Weakness - Investor's Business Daily
LifeStance Health Flirts With Latest Buy Point Despite Ongoing Stock Market Weakness Investor's Business Daily
1 profitable stock to research further and 2 we ignore
LifeStance Health Group Is Up 93%, But The Story Isn't Finished - Simply Wall St
LifeStance Health Group Is Up 93%, But The Story Isn't Finished Simply Wall St
Is LifeStance Health Group (LFST) Undervalued As It Expands Esketamine And TMS Access? - Simply Wall St
Is LifeStance Health Group (LFST) Undervalued As It Expands Esketamine And TMS Access? Simply Wall St
Lifestance Health Group Stock Price Forecast. Should You Buy LFST? - StockInvest.us
Lifestance Health Group Stock Price Forecast. Should You Buy LFST? StockInvest.us
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| FY2026 Q3 | 2026. 09. 30. | Time TBD | — | — | — | — | $455.86M | Reported |
| — | 2026. 08. 06. | After market close (AMC) | $0.08 | — | — | $412.41M | — | Scheduled |
| FY2026 Q2 | 2026. 06. 30. | Time TBD | — | — | — | — | $435.35M | Reported |
| FY2026 Q1 | 2026. 03. 31. | Time TBD | — | — | — | — | $403.48M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 15. | JP Morgan | — | Maintain | Neutral → Neutral | — | JP Morgan: Neutral |
| 2026. 05. 08. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 03. 07. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 02. 27. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 02. 27. | UBS | — | Maintain | Buy → Buy | — | UBS: Buy |
| 2026. 02. 26. | Keybanc | — | Maintain | Overweight → Overweight | — | Keybanc: Overweight |
As of FY2026Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 742,747 | $4.73M | 0.01% | — | New position |
